MétaCan
Menu
Back to cohort

S1132 Improvement in Survival Scores After Ursodiol Use Among Ursodiol Responders vs. Non-Responders in a Community Setting – Newcastle Model and ALBI Score

2021· article· en· W3210136182 on OpenAlexaboutno aff
Mrinalini Buddha, Sadde Mohamed, Jesus E. Romero, Quynh-An Phan, A Pascual Romero, Chukwuma Egwim, Victor Ankoma‐Sey

Bibliographic record

VenueThe American Journal of Gastroenterology · 2021
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineInternal medicineGastroenterologyHepatologyPrimary sclerosing cholangitisCohortPrimary biliary cirrhosisLogistic regressionExact test

Abstract

fetched live from OpenAlex

Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune disorder characterized by portal inflammation and intrahepatic biliary duct destruction. Ursodiol is the first-line treatment for many patients with PBC. Response to ursodiol has been effectively measured by Toronto criteria in previous studies. The primary aim of this study was to assess for the improvement of recently used prognostic scores after ursodiol use among ursodiol responders vs non-responders. The secondary aim was to identify non-responders early to potentially prevent undesired liver decompensation events. Methods: A retrospective cohort study was conducted at Liver Associates of Texas Hepatology outpatient clinic in Houston, Texas. All patients diagnosed with PBC from January 2018-May 2021 were included. Lab and Fibroscan results before and 1 year after starting ursodiol in these patients were collected from their records. Response to Ursodiol was measured using the Toronto criteria [alkaline phosphatase (ALP)≤1.67*ULN are responders and ALP >1.67*ULN are non-responders]. Continuous variables were compared with either the Student’s T-test or Wilcoxon Rank-sum test. Chi-square test, Fisher’s exact test and logistic regression were used for categorical variables. Significance level was set at 5%. Results: Ursodiol response data was available for 111/136 patients with PBC. 65/111 (58.6%) were ursodiol responders and 46/111 (41.4%) were ursodiol non-responders. Majority of the patients were female and there was no significant difference in gender and race/ethnicity distribution. Age, ALP, and APRI score were significantly different among two groups. AST/ALT ratio [p=0.037] and Newcastle Model score [p=0.023] were significantly different after ursodiol use. Newcastle model score was significantly different among ursodiol responders after ursodiol use [p=0.012 vs 0.780]. Non-response to ursodiol is significantly negatively correlated with the Newcastle model score [OR=0.58, p=0.036] and significantly positively correlated with the ALBI score [OR=3.70, p=0.009] in a multiple logistic regression model. Conclusion: Non-responders had a 42% lower Newcastle model score compared to responders after ursodiol use. The ALBI score increased 3.7 times among non-responders compared to responders after ursodiol use. Hence, there is an improvement in Newcastle model score and ALBI score after ursodiol use among responders and can be used to identify non-responders early.Table 1.: Sociodemographic variables in Ursodiol responders vs non-responders among PBC patients

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.272
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicLiver Diseases and ImmunityFrench-language works237,207